ReviewFrontiers in immunology2026
Colorectal cancer liver metastasis: immunosuppressive microenvironment, signaling pathways, and emerging therapeutic strategies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer liver metastasis (CRLM) remains a leading cause of mortality in colorectal cancer. The metastatic liver site is characterized by an immunosuppressive microenvironment enriched with inhibitory immune cells and cytokines, contributing to a poorly inflamed, "cold" tumor phenotype. The progression of CRLM is driven by aberrant activation of oncogenic signaling pathways and a dysfunctional immune landscape, marked by T cell exhaustion and the expansion of immunosuppressive cell populations. This review summarizes the epidemiological characteristics of CRLM and discusses the mechanisms underlying its immunosuppressive microenvironment. We further highlight recent advances in therapeutic strategies, including radiotherapy, interventional approaches, and immune checkpoint inhibitors, providing insights for future mechanistic research and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.